Bile acid has been well known to serve as a hormone in regulating transcriptional activity of Farnesoid X receptor (FXR), an endogenous bile acid nuclear receptor. Moreover, bile acid regulates diverse biological processes, including cholesterol/bile acid metabolism, glucose/lipid metabolism and energy expenditure. Alteration of bile acid metabolism has been revealed in type II diabetic (T2D) patients. FXR-mediated bile acid signaling has been reported to play key roles in improving metabolic parameters in vertical sleeve gastrectomy surgery, implying that FXR is an essential modulator in the metabolic homeostasis. Using a genetic mouse model, intestinal specific FXR-null mice have been reported to be resistant to diet-induced obesity and insulin resistance. Moreover, intestinal specific FXR agonism using gut-specific FXR synthetic agonist has been shown to enhance thermogenesis in brown adipose tissue and browning in white adipose tissue to increase energy expenditure, leading to reduced body weight gain and improved insulin resistance. Altogether, FXR is a potent therapeutic target for the treatment of metabolic diseases. (J Lipid Atheroscler 2017 June;6(1):1-7)
INTRODUCTION
Bile acids are converted from cholesterol in the liver by numerous cytochrome P450 enzymes, including cholesterol-7α-hydroxylase (CYP7A1), steroid 7α-hydroxylase (CYP27A1) and sterol-27-hydroxylase (CYP27A1). 1 Bile acids have been well known to serve as digestive juice to emulsify lipid and promote lipid absorption in the intestinal tract. After endogenous bile acid nuclear receptor Farnesoid X Receptor (FXR) has been reported, 2, 3 bile acids are now widely accepted as metabolic regulator to control whole body homeostasis, such as glucose/lipid metabolism and energy expenditure. Thus, the discovery of endogenous bile acid nuclear receptor FXR proposes new perspectives to understand molecular mechanisms and physiological roles of bile acids and their receptors in various tissues to maintain whole body homeostasis.
FXR: Nuclear bile acid receptor
FXR belongs to nuclear receptor superfamily that contains both DNA and ligand binding domains. 4 FXR heterodimerizes with retinoid X receptor (RXR) and binds to the FXR response element which is localized in the promoter region of FXR target genes. [4] [5] [6] [7] 
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A synthetic bile acid derivative, 6α-ethylchenodeoxycholic acid (6-ECDCA) has been developed and reported with a higher affinity with FXR than the natural bile acids. 9 6-ECDCA recently has been renamed as obeticholic acid, which has recently been approved as a therapeutic reagent for primary biliary cirrhosis (PBC) by Food and Drug Administration, 11, 12 suggesting that FXR is a therapeutic potential target for other metabolic diseases. catalyze a crucial step of hepatic gluconeogenesis. 6, 22, 23 Besides PEPCK, FXR activation represses gene expression of glucose-6-phosphatase (G6pc), which catalyzes the hydrolysis of glucose-6-phosphate to glucose. In addition, www.lipid.or.kr 
Regulation of entero-hepatic bile acid circulation

FXR activation also increases glycogen levels in the liver
as via enhancing downstream insulin receptor signaling. 
Physiological roles of FXR in the gut to modulate whole body metabolism
Recent study has shown that beneficial improvements by vertical sleeve gastrectomy (VSG) were diminished in FXR-null mice. 30 These results reported that VSG in wild type mice increased circulating bile acids and changed gut microbial communities. Thus, FXR signaling is an important molecular underpinning for the beneficial effects of the VSG. 30 In addition to the critical roles of FXR in VSG, a recent study has proposed therapeutic roles of FXR to protect against diet-induced obesity. By using gut-specific FXR synthetic agonist, named Fexaramine, intestinal specific FXR agonism largely increased the thermogenesis and mitochondrial oxidative phosphorylation in brown adipose tissues. 31 The intestinal FXR agonism-mediated fat remodeling also led to increased browning of white adipose tissue. Thus, intestinal FXR agonism stimulated energy expenditure in brown and white adipose tissue, leading to increase whole body energy metabolism. 31 The molecular mechanisms of how intestinal FXR agonism increased whole body energy metabolism remains still unclear.
In contrast, another recent study has reported that ablation of intestine-specific FXR led to anti-obesity in obese animal models. 32 As previously mentioned, FXR activation in the intestine is able to repress CYP7A1 (Fig. 4) .
CONCLUSION
Though bariatric surgery has been well known to improve metabolic parameters in the patients, the molecular mechanisms for beneficial effects still remain unclear. As reported, patients with bariatric surgery usually exhibit elevated circulating bile acid levels, FGF19, and
Glucagon-like peptide 1 (GLP-1). [34] [35] [36] Given that bile acids are the endogenous ligand for nuclear receptor FXR, the physiological roles of FXR has been widely accepted as a novel therapeutic target for metabolic syndromes.
Though numerous studies have revealed various physiological functions of FXR in the animal models of metabolic diseases, the development of synthetic modulator to regulate FXR transcriptional activities still needs to be required. Since FXR has been reported as a critical molecule to improve beneficial metabolic parameter in VSG using animal model, development of novel synthetic modulator for FXR would be useful therapeutic target for metabolic diseases.
